Stocks · News reference
Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials
Takeda shares positive Phase 3 data for its oral psoriasis drug zasocitinib, showing high skin clearance ahead of its planned FDA filing.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 17, 2026, 5:08 PM
- Checked
- Jul 17, 2026, 5:08 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
Read original at benzingaVinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’
Vinod Khosla says AI is revolutionizing drug discovery, but drug testing needs to catch up with more human-relevant methods.
Read original at benzingaDepartment Of Veterans Affairs Awards Takeda $5.6B Contract for Drugs And Biologicals Through 2031
https://sam.gov/opp/b8e3db55feb04369933f735cc6cda9aa/view
Read original at benzinga